Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP

Summary Although 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the cor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2020-03, Vol.188 (6), p.860-871
Hauptverfasser:	Jeon, Young‐Woo, O, Joo‐Hyun, Park, Kyung‐Sin, Min, Gi June, Park, Sung‐Soo, Yoon, Jae‐Ho, Eom, Ki‐Seong, Min, Chang‐Ki, Cho, Seok‐Goo
Format:	Artikel
Sprache:	eng
Schlagworte:	Autografts Clinical trials Cyclophosphamide Doxorubicin Haematological Malignancy – Clinical Hematology Hematopoietic stem cells interim 18F‐FDG PET Lymphoma Mantle cell lymphoma Metabolism Monoclonal antibodies Patients Positron emission tomography Prednisolone prognosis Research Paper Rituximab R‐CHOP Stem cell transplantation Targeted cancer therapy Tomography treatment response Vincristine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Although 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the correlations of interim PET (iPET) and end‐of‐treatment PET (ePET) response with survival outcomes in 89 consecutive advanced MCL patients treated with frontline R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone). iPET positivity was strongly associated with inferior five‐year overall survival (OS) [hazard ratio (HR) 7·84, P
ISSN:	0007-1048 1365-2141
DOI:	10.1111/bjh.16257